Status and phase
Conditions
Treatments
About
The purpose of this study is to determine the diagnostic utility of 89Zr-panitumumab to identify metastatic lesion(s) in subjects with head and neck squamous cell carcinoma (HNSCC).
Full description
PRIMARY OBJECTIVE(S):
SECONDARY OBJECTIVE(S):
Enrollment
Sex
Ages
Volunteers
Inclusion criteria
Age ≥ 19 years.
Biopsy confirmed diagnosis of squamous cell carcinoma of the head and neck.
Subjects diagnosed with any T stage, any subsite within the head and neck. Subjects with recurrent disease or a new primary will be allowed.
Must have standard of care 18F-FDG-PET/CT scan ≤ 30 days of Day 0 with suspected metastatic lesions.
Have acceptable hematological status, coagulation status, kidney function, and liver function including the following clinical results:
Exclusion criteria
Primary purpose
Allocation
Interventional model
Masking
60 participants in 2 patient groups
Loading...
Central trial contact
Roan C Raymundo, BS; Grace Yi
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal